|
Mechanismneuraminidase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.SE |
First Approval Date01 Jun 1999 |
/ Not yet recruitingNot Applicable Follow-up survey for comparing stable dosing with a symptom based as needed-regimen” in moderate and severe persitent asthma.
/ Not yet recruitingNot Applicable Seretide vs Flixotide in mild persistent asthma (GINAII)
/ Not yet recruitingNot Applicable A Multicentre, Randomised, Double-Blind, Parallel Group, 24 Week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/250mcg with Salmeterol 50mcg Both Delivered Twice Daily via the DISKUS/ACCUHALER Inhaler on Lung Function and Dyspnoea in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
100 Clinical Results associated with GlaxoSmithkline AB
0 Patents (Medical) associated with GlaxoSmithkline AB
[GlaxoSmithKline requires additional consideration of the national procurement of cancer vaccine: Procurement of HPV vaccine is not consistent with good scientific, ethical and moral practice].
Article
Author: Flaten, Olav ; Thor, Johan
100 Deals associated with GlaxoSmithkline AB
100 Translational Medicine associated with GlaxoSmithkline AB